Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence trial of fluticasone propionate + salmeterol inhalation powder versus Advair Diskus in asthma
2022-002977-27Phase 3Completed
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in asthma comparing Test generic fluticasone propionate + salmeterol, Advair Diskus active comparator and Placebo (3 arms). Primary endpoint: Area under the serial FEV1-time curve from 0 to 12 hours on Day 1. Started Dec 2022; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-002977-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002977-27.